TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global and United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Report & Forecast 2022-2028

Global and United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Report & Forecast 2022-2028

  • Category:Life Sciences
  • Published on : 07 October 2022
  • Pages :105
  • Formats:
  • Report Code:SMR-7417570
OfferClick for best price

Best Price: $3480

Squamous NonSmall Cell Lung Cancer Therapeutics Market Size, Share 2022


Market Analysis and Insights: Global Squamous NonSmall Cell Lung Cancer Therapeutics Market

The global Squamous NonSmall Cell Lung Cancer Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Squamous NonSmall Cell Lung Cancer Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Squamous NonSmall Cell Lung Cancer Therapeutics market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Squamous NonSmall Cell Lung Cancer Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Squamous NonSmall Cell Lung Cancer Therapeutics market.

Global Squamous NonSmall Cell Lung Cancer Therapeutics Scope and Market Size

Squamous Non-Small Cell Lung Cancer Therapeutics market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Squamous Non-Small Cell Lung Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Squamous Non-Small Cell Lung Cancer Therapeutics market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type

BMS-906024

Buparlisib Hydrochloride

FP-1039

Ipilimumab

JNJ-42756493

Lenvatinib

Others

Segment by Application

Research Center

Hospital

Clinic

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

By Company

Ascenta Therapeutics, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Genentech, Inc.

Incyte Corporation

Johnson & Johnson

MacroGenics, Inc.

Novartis AG

Oncogenex Pharmaceuticals, Inc.

PsiOxus Therapeutics Limited

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Squamous NonSmall Cell Lung Cancer Therapeutics product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Squamous NonSmall Cell Lung Cancer Therapeutics, with price, sales, revenue, and global market share of Squamous NonSmall Cell Lung Cancer Therapeutics from 2019 to 2022.

Chapter 3, the Squamous NonSmall Cell Lung Cancer Therapeutics competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Squamous NonSmall Cell Lung Cancer Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Squamous NonSmall Cell Lung Cancer Therapeutics market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Squamous NonSmall Cell Lung Cancer Therapeutics.

Chapter 13, 14, and 15, to describe Squamous NonSmall Cell Lung Cancer Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Squamous NonSmall Cell Lung Cancer Therapeutics Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global and United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Report & Forecast 2022-2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 105 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Study Coverage
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size for the Year 2017-2028
1.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size for the Year 2017-2028
1.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Squamous Non-Small Cell Lung Cancer Therapeutics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
1.4.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
1.4.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
1.4.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
1.4.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Squamous Non-Small Cell Lung Cancer Therapeutics by Type
2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment by Type
2.1.1 BMS-906024
2.1.2 Buparlisib Hydrochloride
2.1.3 FP-1039
2.1.4 Ipilimumab
2.1.5 JNJ-42756493
2.1.6 Lenvatinib
2.1.7 Others
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017, 2022 & 2028)
2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028)
2.4 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017, 2022 & 2028)
2.5 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028)
3 Squamous Non-Small Cell Lung Cancer Therapeutics by Application
3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment by Application
3.1.1 Research Center
3.1.2 Hospital
3.1.3 Clinic
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017, 2022 & 2028)
3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028)
3.4 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017, 2022 & 2028)
3.5 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028)
4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Competitor Landscape by Company
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Company
4.1.1 Top Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Ranked by Revenue (2021)
4.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Player (2017-2022)
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Concentration Ratio (CR)
4.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Squamous Non-Small Cell Lung Cancer Therapeutics in 2021
4.2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Headquarters, Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Headquarters and Area Served
4.3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Company
4.5.1 Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2020, 2021 & 2022)
5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2017-2028)
5.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2017-2022
5.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.1.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.4.2 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Ascenta Therapeutics, Inc.
7.1.1 Ascenta Therapeutics, Inc. Company Details
7.1.2 Ascenta Therapeutics, Inc. Business Overview
7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.1.4 Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.1.5 Ascenta Therapeutics, Inc. Recent Development
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Company Details
7.2.2 AstraZeneca Plc Business Overview
7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.2.4 AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.2.5 AstraZeneca Plc Recent Development
7.3 AVEO Pharmaceuticals, Inc.
7.3.1 AVEO Pharmaceuticals, Inc. Company Details
7.3.2 AVEO Pharmaceuticals, Inc. Business Overview
7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.3.4 AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.3.5 AVEO Pharmaceuticals, Inc. Recent Development
7.4 Bayer AG
7.4.1 Bayer AG Company Details
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.4.4 Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.4.5 Bayer AG Recent Development
7.5 BIND Therapeutics, Inc.
7.5.1 BIND Therapeutics, Inc. Company Details
7.5.2 BIND Therapeutics, Inc. Business Overview
7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.5.4 BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.5.5 BIND Therapeutics, Inc. Recent Development
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Company Details
7.6.2 Boehringer Ingelheim GmbH Business Overview
7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.6.4 Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.6.5 Boehringer Ingelheim GmbH Recent Development
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Company Details
7.7.2 Bristol-Myers Squibb Company Business Overview
7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.7.4 Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.7.5 Bristol-Myers Squibb Company Recent Development
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Company Details
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.8.4 Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.8.5 Eli Lilly and Company Recent Development
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Company Details
7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.9.4 F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.9.5 F. Hoffmann-La Roche Ltd. Recent Development
7.10 Five Prime Therapeutics, Inc.
7.10.1 Five Prime Therapeutics, Inc. Company Details
7.10.2 Five Prime Therapeutics, Inc. Business Overview
7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.10.4 Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.10.5 Five Prime Therapeutics, Inc. Recent Development
7.11 Genentech, Inc.
7.11.1 Genentech, Inc. Company Details
7.11.2 Genentech, Inc. Business Overview
7.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.11.4 Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.11.5 Genentech, Inc. Recent Development
7.12 Incyte Corporation
7.12.1 Incyte Corporation Company Details
7.12.2 Incyte Corporation Business Overview
7.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.12.4 Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.12.5 Incyte Corporation Recent Development
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Company Details
7.13.2 Johnson & Johnson Business Overview
7.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.13.4 Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.13.5 Johnson & Johnson Recent Development
7.14 MacroGenics, Inc.
7.14.1 MacroGenics, Inc. Company Details
7.14.2 MacroGenics, Inc. Business Overview
7.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.14.4 MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.14.5 MacroGenics, Inc. Recent Development
7.15 Novartis AG
7.15.1 Novartis AG Company Details
7.15.2 Novartis AG Business Overview
7.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.15.4 Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.15.5 Novartis AG Recent Development
7.16 Oncogenex Pharmaceuticals, Inc.
7.16.1 Oncogenex Pharmaceuticals, Inc. Company Details
7.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
7.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.16.4 Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.16.5 Oncogenex Pharmaceuticals, Inc. Recent Development
7.17 PsiOxus Therapeutics Limited
7.17.1 PsiOxus Therapeutics Limited Company Details
7.17.2 PsiOxus Therapeutics Limited Business Overview
7.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.17.4 PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.17.5 PsiOxus Therapeutics Limited Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
Table 4. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 5. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Squamous Non-Small Cell Lung Cancer Therapeutics Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Player, 2017-2022
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2021)
Table 15. Top Players of Squamous Non-Small Cell Lung Cancer Therapeutics in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Ascenta Therapeutics, Inc. Company Details
Table 31. Ascenta Therapeutics, Inc. Business Overview
Table 32. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 33. Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 34. Ascenta Therapeutics, Inc. Recent Development
Table 35. AstraZeneca Plc Company Details
Table 36. AstraZeneca Plc Business Overview
Table 37. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 38. AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 39. AstraZeneca Plc Recent Development
Table 40. AVEO Pharmaceuticals, Inc. Company Details
Table 41. AVEO Pharmaceuticals, Inc. Business Overview
Table 42. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 43. AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 44. AVEO Pharmaceuticals, Inc. Recent Development
Table 45. Bayer AG Company Details
Table 46. Bayer AG Business Overview
Table 47. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 48. Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Bayer AG Recent Development
Table 50. BIND Therapeutics, Inc. Company Details
Table 51. BIND Therapeutics, Inc. Business Overview
Table 52. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 53. BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 54. BIND Therapeutics, Inc. Recent Development
Table 55. Boehringer Ingelheim GmbH Company Details
Table 56. Boehringer Ingelheim GmbH Business Overview
Table 57. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 58. Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Boehringer Ingelheim GmbH Recent Development
Table 60. Bristol-Myers Squibb Company Company Details
Table 61. Bristol-Myers Squibb Company Business Overview
Table 62. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 63. Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Recent Development
Table 65. Eli Lilly and Company Company Details
Table 66. Eli Lilly and Company Business Overview
Table 67. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 68. Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Eli Lilly and Company Recent Development
Table 70. F. Hoffmann-La Roche Ltd. Company Details
Table 71. F. Hoffmann-La Roche Ltd. Business Overview
Table 72. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 73. F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 74. F. Hoffmann-La Roche Ltd. Recent Development
Table 75. Five Prime Therapeutics, Inc. Company Details
Table 76. Five Prime Therapeutics, Inc. Business Overview
Table 77. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 78. Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Five Prime Therapeutics, Inc. Recent Development
Table 80. Genentech, Inc. Company Details
Table 81. Genentech, Inc. Business Overview
Table 82. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 83. Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Genentech, Inc. Recent Development
Table 85. Incyte Corporation Company Details
Table 86. Incyte Corporation Business Overview
Table 87. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 88. Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 89. Incyte Corporation Recent Development
Table 90. Johnson & Johnson Company Details
Table 91. Johnson & Johnson Business Overview
Table 92. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 93. Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Johnson & Johnson Recent Development
Table 95. MacroGenics, Inc. Company Details
Table 96. MacroGenics, Inc. Business Overview
Table 97. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 98. MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 99. MacroGenics, Inc. Recent Development
Table 100. Novartis AG Company Details
Table 101. Novartis AG Business Overview
Table 102. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 103. Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 104. Novartis AG Recent Development
Table 105. Oncogenex Pharmaceuticals, Inc. Company Details
Table 106. Oncogenex Pharmaceuticals, Inc. Business Overview
Table 107. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 108. Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 109. Oncogenex Pharmaceuticals, Inc. Recent Development
Table 110. PsiOxus Therapeutics Limited Company Details
Table 111. PsiOxus Therapeutics Limited Business Overview
Table 112. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 113. PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 114. PsiOxus Therapeutics Limited Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Product Picture
Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size 2017-2028 (US$ Million)
Figure 4. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size 2017-2028 (US$ Million)
Figure 6. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share in Global 2017-2028
Figure 7. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 8. Product Picture of BMS-906024
Figure 9. Product Picture of Buparlisib Hydrochloride
Figure 10. Product Picture of FP-1039
Figure 11. Product Picture of Ipilimumab
Figure 12. Product Picture of JNJ-42756493
Figure 13. Product Picture of Lenvatinib
Figure 14. Product Picture of Others
Figure 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type in 2022 & 2028
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028) & (US$ Million)
Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2017-2028)
Figure 18. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type in 2022 & 2028
Figure 19. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028) & (US$ Million)
Figure 20. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2017-2028)
Figure 21. Product Picture of Research Center
Figure 22. Product Picture of Hospital
Figure 23. Product Picture of Clinic
Figure 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application in 2022 & 2028
Figure 25. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028) & (US$ Million)
Figure 26. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2017-2028)
Figure 27. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application in 2022 & 2028
Figure 28. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028) & (US$ Million)
Figure 29. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2017-2028)
Figure 30. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 31. U.S. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 32. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 34. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 38. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 40. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Australia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Taiwan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Indonesia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Thailand Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Malaysia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 49. Philippines Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 51. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 53. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 55. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 57. U.A.E Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 58. Ascenta Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 59. AstraZeneca Plc Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 60. AVEO Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 61. Bayer AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 62. BIND Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 63. Boehringer Ingelheim GmbH Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 64. Bristol-Myers Squibb Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 65. Eli Lilly and Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 66. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 67. Five Prime Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 68. Genentech, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 69. Incyte Corporation Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 70. Johnson & Johnson Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 71. MacroGenics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 72. Novartis AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 73. Oncogenex Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 74. PsiOxus Therapeutics Limited Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount